Blood Cancer Drugs Market Report 2025

This Blood Cancer Drugs market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The blood cancer drugs market size has grown strongly in recent years. It will grow from $74.78 billion in 2024 to $80.79 billion in 2025 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to advancements in research and development, aging population, increased awareness and early diagnosis, regulatory approvals.

The blood cancer drugs market size is expected to see strong growth in the next few years. It will grow to $106.8 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing disease prevalence, emerging markets, supportive care. Major trends in the forecast period include research and development investments, combination therapies, biomarker identification, immunotherapy advancements, personalized medicine.

The blood cancer drugs market is experiencing growth due to the escalating number of deaths and the rising prevalence of blood cancer cases worldwide. Various forms of blood cancers, including lymphoma, leukemia, myeloma, and others, have distinct risk factors. Some can be managed or prevented through drug therapies, while others may result in fatalities. According to a report by Bristol-Myers Squibb Company, it is projected that by 2040, over 1.85 million new blood cancer cases will be diagnosed globally. These cases will include 918,872 instances of lymphoma, 656,345 of leukemia, and 275,047 of myeloma. The report further estimates that by 2040, around 1,100,000 deaths will occur worldwide due to blood cancer. The increasing number of deaths and the surging incidence of blood cancer cases are propelling the growth of the blood cancer drug market.

Major companies operating in the blood cancer drugs market are focusing on developing new drugs and seeking FDA approval to gain a competitive edge. FDA approval refers to the formal authorization granted by the United States Food and Drug Administration (FDA) for a pharmaceutical product to be legally marketed and sold in the U.S. For example, in March 2024, Bristol Myers Squibb, a US-based pharmaceutical company, received FDA approval for its first and only CAR T-cell therapy for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This accelerated approval allows its use in patients who have previously received at least two treatments, including a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor. Based on the TRANSCEND CLL 004 trial, Breyanzi showed a 20% complete response rate and a median duration of response of 35.3 months among responders.

Major players in the blood cancer drugs market are actively engaged in the development of novel drugs and pursuing FDA approval to gain a competitive edge in the industry. FDA approval for drugs is the formal authorization issued by the United States Food and Drug Administration (FDA) for the legal marketing and sale of a pharmaceutical product in the United States. These approvals hold immense value in the market. In May 2023, the FDA granted its approval to Epcoritamab, commercially known as Epkinly, for the treatment of diffuse large B-cell lymphoma (DLBCL) in patients who have undergone at least two prior lines of systemic therapy. Epkinly, classified as a CD20xCD3 T-cell engager, exhibited significant efficacy during clinical trials, with a 61% tumor shrinkage rate in patients who had previously received multiple treatments. This approval serves as a noteworthy addition to the available treatment options for DLBCL.

In July 2022, GSK, a prominent pharmaceutical company based in the UK, completed the acquisition of Sierra Oncology for an undisclosed sum. This strategic acquisition bolsters GSK's oncology portfolio. Sierra Oncology, headquartered in the United States, specializes in the development of cancer drugs, including treatments for blood cancers.

Major companies operating in the blood cancer drugs market include Amgen Inc., AstraZeneca PLC, Bayer AG, Eli Lilly and Company Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Astellas Pharma Inc., Roche Holding AG, Merck & Co. Inc., Gilead Sciences Inc., Sanofi S.A., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Kyowa Kirin Co. Ltd., Menarini Group, Millennium Pharmaceuticals Inc., Mundipharma International Limited, Mylan N.V., Ono Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Pharmacyclics LLC, Regeneron Pharmaceuticals Inc., Seattle Genetics Inc., Servier Laboratories, Shire PLC, Spectrum Pharmaceuticals Inc., Taiho Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Tolero Pharmaceuticals Inc., UCB S.A., Vertex Pharmaceuticals Incorporated.

Blood cancer drugs are pharmaceutical treatments employed to combat blood cancer by harnessing the body's immune system to slow down the proliferation of cancer cells. These treatments encompass a range of modalities, including chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant, all tailored to address blood cancer effectively.

The primary categories of blood cancer drugs target leukemia and lymphoma. Leukemia pertains to a form of cancer affecting blood-forming tissues, particularly the bone marrow and lymphatic system. Various drug formulations are used in this context, including rituximab (Rituaxan/Mabthera), imatinib (Gleevec/Glivec), lenalidomide (Revlimid), bortezomib (Velcade), nilotinib (Tasigna), pomalidomide (Pomalyst), azacitidine (Fidanza), carfilzomib (Kyphosis), brentuximabvedotin (Adcetris), among others. These drugs are administered through diverse treatment approaches, spanning key findings, chemotherapeutic methods, monoclonal antibodies/targeted therapies, and immunotherapeutic interventions.

The blood cancer drugs market research report is one of a series of new reports that provides blood cancer drugs market statistics, including blood cancer drugs industry global market size, regional shares, competitors with a blood cancer drugs market share, detailed blood cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the blood cancer drugs industry. This blood cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

North America was the largest region in the blood cancer drugs market in 2024. Middle East is expected to be the fastest-growing region in the blood cancer drugs market during the forecast period. The regions covered in the blood cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the blood cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The blood cancer drugs market consists of sales Altretamine, Bendamustine, Bendamustine, and Carboplatin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.